Endocrine Abstracts

The treatment of type 1 diabetes is currently restricted to insulin therapy. However, achieving and maintaining strict glycaemic control is a demanding task for many patients and increases the risk of hypoglycaemia and weight gain. This makes new treatments complementary to insulin of interest. In type 2 diabetes, the combination of insulin and a GLP-1 receptor agonist improves glycaemic control, induces weight loss and reduces daily insulin dose needed. However, only little e...

GLP-1 is one of the two known incretin hormones (the other one being GIP), which have the ability to stimulate insulin secretion whenever glucose concentrations are above a certain permissive threshold. The incretin effect (greater stimulation of insulin secretory responses with oral as compared to matched intravenous glucose administration) is reduced in patients with type 2 diabetes, thus the question needed to be addressed, whether there is hyposecretion or impaired action ...

In 1996, we showed that GLP-1 is a satiety hormone in humans, and increased post-prandial GLP-1 levels following high protein meals have shown to be at least partially responsible for the high satiating effect of protein. The natural ligands to stimulate GLP-1 release seem to be peptide fragments and monoacylglycerides.The once-daily GLP-1 analogue liraglutide at doses up to 3.0 mg was compared with placebo or orlistat over 104 weeks as adjunct to diet a...